Rachel S van der Post1, Ingrid P Vogelaar2, Peggy Manders2, Lizet E van der Kolk3, Annemieke Cats4, Liselotte P van Hest5, Rolf Sijmons6, Cora M Aalfs7, Margreet G E M Ausems8, Encarna B Gómez García9, Anja Wagner10, Frederik J Hes11, Neeltje Arts2, Arjen R Mensenkamp2, J Han van Krieken1, Nicoline Hoogerbrugge2, Marjolijn J L Ligtenberg12. 1. Department of Pathology, Radboud university medical center, Nijmegen, The Netherlands. 2. Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands. 3. Family Cancer Clinic, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 4. Department of Gastroenterology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 5. Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands. 6. Department of Genetics, University Medical Center Groningen, University of Groningen, The Netherlands. 7. Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands. 8. Department of Medical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands. 9. Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands. 10. Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands. 11. Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands. 12. Department of Pathology, Radboud university medical center, Nijmegen, The Netherlands; Department of Human Genetics, Radboud university medical center, Nijmegen, The Netherlands. Electronic address: Marjolijn.Ligtenberg@radboudumc.nl.
Abstract
BACKGROUND & AIMS: Germline mutations in the cadherin 1, type 1, E-cadherin gene (CDH1) cause a predisposition to gastric cancer. We evaluated the ability of the internationally accepted hereditary diffuse gastric cancer (HDGC) criteria to identify individuals with pathogenic mutations in CDH1, and assessed their outcomes. The criteria were as follows: families with 2 or more cases of gastric cancer, with at least 1 patient diagnosed with diffuse gastric cancer (DGC) before age 50; families with 3 or more cases of DGC; families with 1 DGC before the age of 40; and families with a history of DGC and lobular breast cancer, with 1 diagnosis before the age of 50. METHODS: We collected results of a CDH1 mutation analysis of 578 individuals from 499 families tested in The Netherlands between 1999 and 2014 (118 families met the HDGC criteria for testing and 236 did not; there were 145 families with incomplete data and/or availability of only first-degree relatives). Data were linked with family histories and findings from clinical and pathology analyses. The Kaplan-Meier method and Cox regression analysis were used to evaluate the overall survival of patients with and without CDH1 mutations. RESULTS: In a cohort study in The Netherlands, the HDGC criteria identified individuals with a germline CDH1 mutation with a positive predictive value of 14% and 89% sensitivity. There were 18 pathogenic CDH1 mutations in 499 families (4%); 16 of these mutations were detected in the 118 families who met the HDGC criteria for testing. One pathogenic CDH1 mutation was detected in the 236 families who did not meet HDGC criteria and 1 in the 145 families with incomplete data and/or availability of only first-degree relatives. No CDH1 mutations were found in the 67 families whose members developed intestinal-type gastric cancer, or in the 22 families whose families developed lobular breast cancer. Among patients who fulfilled the HDGC criteria and had pathogenic CDH1 mutations, 36% survived for 1 year and 4% survived for 5 years; among patients who fulfilled the HDGC criteria but did not carry pathogenic CDH1 mutations, 48% survived for 1 year and 13% survived for 5 years (P = .014 for comparative survival analysis between patients with and without a CDH1 mutation). CONCLUSIONS: All individuals with a CDH1 mutation had a personal or family history of diffuse gastric cancer. Patients with gastric cancer and germline CDH1 mutations had shorter survival times than patients who met the HDGC criteria but did not have CDH1 mutations.
BACKGROUND & AIMS: Germline mutations in the cadherin 1, type 1, E-cadherin gene (CDH1) cause a predisposition to gastric cancer. We evaluated the ability of the internationally accepted hereditary diffuse gastric cancer (HDGC) criteria to identify individuals with pathogenic mutations in CDH1, and assessed their outcomes. The criteria were as follows: families with 2 or more cases of gastric cancer, with at least 1 patient diagnosed with diffuse gastric cancer (DGC) before age 50; families with 3 or more cases of DGC; families with 1 DGC before the age of 40; and families with a history of DGC and lobular breast cancer, with 1 diagnosis before the age of 50. METHODS: We collected results of a CDH1 mutation analysis of 578 individuals from 499 families tested in The Netherlands between 1999 and 2014 (118 families met the HDGC criteria for testing and 236 did not; there were 145 families with incomplete data and/or availability of only first-degree relatives). Data were linked with family histories and findings from clinical and pathology analyses. The Kaplan-Meier method and Cox regression analysis were used to evaluate the overall survival of patients with and without CDH1 mutations. RESULTS: In a cohort study in The Netherlands, the HDGC criteria identified individuals with a germline CDH1 mutation with a positive predictive value of 14% and 89% sensitivity. There were 18 pathogenic CDH1 mutations in 499 families (4%); 16 of these mutations were detected in the 118 families who met the HDGC criteria for testing. One pathogenic CDH1 mutation was detected in the 236 families who did not meet HDGC criteria and 1 in the 145 families with incomplete data and/or availability of only first-degree relatives. No CDH1 mutations were found in the 67 families whose members developed intestinal-type gastric cancer, or in the 22 families whose families developed lobular breast cancer. Among patients who fulfilled the HDGC criteria and had pathogenic CDH1 mutations, 36% survived for 1 year and 4% survived for 5 years; among patients who fulfilled the HDGC criteria but did not carry pathogenic CDH1 mutations, 48% survived for 1 year and 13% survived for 5 years (P = .014 for comparative survival analysis between patients with and without a CDH1 mutation). CONCLUSIONS: All individuals with a CDH1 mutation had a personal or family history of diffuse gastric cancer. Patients with gastric cancer and germline CDH1 mutations had shorter survival times than patients who met the HDGC criteria but did not have CDH1 mutations.
Authors: Winifred Lo; Bin Zhu; Arvind Sabesan; Ho-Hsiang Wu; Astin Powers; Rebecca A Sorber; Sarangan Ravichandran; Ina Chen; Lucas A McDuffie; Humair S Quadri; Joal D Beane; Kathleen Calzone; Markku M Miettinen; Stephen M Hewitt; Christopher Koh; Theo Heller; Sholom Wacholder; Udo Rudloff Journal: J Med Genet Date: 2019-02-11 Impact factor: 6.318
Authors: Kristy Lee; Kate Krempely; Maegan E Roberts; Michael J Anderson; Fatima Carneiro; Elizabeth Chao; Katherine Dixon; Joana Figueiredo; Rajarshi Ghosh; David Huntsman; Pardeep Kaurah; Chimene Kesserwan; Tyler Landrith; Shuwei Li; Arjen R Mensenkamp; Carla Oliveira; Carolina Pardo; Tina Pesaran; Matthew Richardson; Thomas P Slavin; Amanda B Spurdle; Mackenzie Trapp; Leora Witkowski; Charles S Yi; Liying Zhang; Sharon E Plon; Kasmintan A Schrader; Rachid Karam Journal: Hum Mutat Date: 2018-11 Impact factor: 4.878
Authors: Bar Chikman; Tima Davidson; Hasan Kais; Igor Jeroukhimov; Ari Leshno; Judith Sandbank; Ariel Halevy; Ron Lavy Journal: Fam Cancer Date: 2016-01 Impact factor: 2.375
Authors: Vanessa R Blair; Maybelle McLeod; Fátima Carneiro; Daniel G Coit; Johanna L D'Addario; Jolanda M van Dieren; Kirsty L Harris; Nicoline Hoogerbrugge; Carla Oliveira; Rachel S van der Post; Julie Arnold; Patrick R Benusiglio; Tanya M Bisseling; Alex Boussioutas; Annemieke Cats; Amanda Charlton; Karen E Chelcun Schreiber; Jeremy L Davis; Massimiliano di Pietro; Rebecca C Fitzgerald; James M Ford; Kimberley Gamet; Irene Gullo; Richard H Hardwick; David G Huntsman; Pardeep Kaurah; Sonia S Kupfer; Andrew Latchford; Paul F Mansfield; Takeshi Nakajima; Susan Parry; Jeremy Rossaak; Haruhiko Sugimura; Magali Svrcek; Marc Tischkowitz; Toshikazu Ushijima; Hidetaka Yamada; Han-Kwang Yang; Adrian Claydon; Joana Figueiredo; Karyn Paringatai; Raquel Seruca; Nicola Bougen-Zhukov; Tom Brew; Simone Busija; Patricia Carneiro; Lynn DeGregorio; Helen Fisher; Erin Gardner; Tanis D Godwin; Katharine N Holm; Bostjan Humar; Caroline J Lintott; Elizabeth C Monroe; Mark D Muller; Enrique Norero; Yasmin Nouri; Joana Paredes; João M Sanches; Emily Schulpen; Ana S Ribeiro; Andrew Sporle; James Whitworth; Liying Zhang; Anthony E Reeve; Parry Guilford Journal: Lancet Oncol Date: 2020-08 Impact factor: 41.316
Authors: M Aronson; C Swallow; A Govindarajan; K Semotiuk; Z Cohen; P Kaurah; L Velsher; I Ambus; K Buckley; C Forster-Gibson; W S Meschino; A Blumenthal; R H Kim; S Brar Journal: Curr Oncol Date: 2020-05-01 Impact factor: 3.677